Cite
HARVARD Citation
Cheng, H. et al. (2021). Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial. Lancet oncology. 22 (11), pp. 1609-1617. [Online].